Assessing Patient Engagement and Understanding in Hepatic Encephalopathy Clinical Research
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatic Encephalopathy
- Sponsor
- Power Life Sciences Inc.
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Number of hepatic encephalopathy patients who remain in clinical trial until completion
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in hepatic encephalopathy clinical trials. Uncovering these factors is essential to enhance the relevance and efficacy of future research endeavors.
In essence, this trial aims to deepen understanding of the factors influencing participation in hepatic encephalopathy clinical trials. Elevating participation rates could expedite the development of innovative treatments for this challenging condition.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed Written Informed Consent
- •Aged ≥ 18 years old
- •No prior treatment for hepatic encephalopathy
Exclusion Criteria
- •Participant is actively receiving study therapy in another
- •Inability to provide written informed consent
- •Women of childbearing potential without a negative pregnancy test; or women who are lactating.
Outcomes
Primary Outcomes
Number of hepatic encephalopathy patients who remain in clinical trial until completion
Time Frame: 12 months
Rate of patients who decide to join in a hepatic encephalopathy clinical trial
Time Frame: 3 months